GlaxoSmithKline Pharmaceuticals Q3 Results
- BSE: 500660
- NSE: GLAXO
- ISIN: INE159A01016
- Sector: Biotechnology & Drugs
BSE
2,404.30
11.05 (0.46%)
11.05 (0.46%)Volume2.52 K
Updated: Mon 13 Apr, 2026 | 15:29:33
NSE
2,414.2020.20 (0.84%)
20.20 (0.84%)Volume63.74 K
Updated: Mon 13 Apr, 2026 | 15:50:13
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Income₹1,041.26 Cr.(9.67%)
- Operating Profit₹351.02 Cr.(28.52%)
- Profit After Tax₹295.62 Cr.(28.60%)
- Operating Margin33.71%(17.19%)
Note: Comparison is on YoY basis
Quarterly - GlaxoSmithKline Pharmaceuticals Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 690.24 | 705.92 | 4.32% | 767.62 | 2.06% |
| Depreciation/ Amortization | 20.32 | 16.86 | 16.58% | 17.11 | 8.09% |
| Operating Income | 351.02 | 304.85 | 10.28% | 37.64 | 28.52% |
| Net Income | 295.62 | 252.50 | 14.81% | 45.72 | 28.60% |
| Other Operating Expenses Total | 154.22 | 153.86 | 2.38% | 129.01 | -11.16% |
| Net Income Before Taxes | 399.93 | 343.81 | 12.97% | 65.43 | 29.81% |
| Total Revenue | 1,041.26 | 1,010.77 | 6.26% | 805.26 | 9.67% |
| Selling/ General/ Admin Expenses Total | 151.88 | 150.71 | 10.02% | 141.35 | 21.76% |
| Diluted Normalized EPS | 16.67 | 14.47 | 10.47% | 9.44 | 22.81% |